Psychiatric Times

12/09/2025

🚨NDA Submission: has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia in adults.

Teva Pharmaceuticals has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia.

12/08/2025

Psychedelics for mental health disorders: According to new positive phase 2 data, Incannex Healthcare's PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder, showed statistically significant and clinically meaningful improvements in patients with moderate to severe anxiety. We chatted with Lou Barbato, MD, the chief medical officer of Incannex, to learn more.

Psychiatric Times is the connection to Psychiatry and Mental Health, featuring clinical updates, expert views, and research news in multimedia formats.

12/04/2025

❄️ The December issue of Psychiatric Times is now live! This month, we take closer look at the IV lorazepam shortage and the concept of psychopathology.

Download the issue now and follow along as articles are shared throughout the month.https://cdn.sanity.io/files/0vv8moc6/psychtimes/380554b5a2e6ecc1bf177048b282b991f783cf9d.pdf

12/02/2025

Today is 🫶

Check out this curated list of places where you can make a difference in psychiatry with your donations. Where are you donating today?
https://www.psychiatrictimes.com/view/this-giving-tuesday-give-back-to-psychiatry

12/02/2025

Our December theme: 2025 Wrap Up.

What did you learn in 2025? What was the most important psychiatric advancement in 2025? Do you have practice tips to offer your fellow mental health clinicians? Share with us! https://www.psychiatrictimes.com/view/presenting-our-december-theme-2025-wrap-up

11/27/2025

This season, we give thanks for the mental health professionals, researchers, and advocates who work tirelessly to support wellness and healing. 🦃💙
Wishing you peace and connection this Thanksgiving.

11/26/2025

Need CME credit? This holiday weekend, check out our latest CME article on the assessment and management of su***de risk in bipolar disorder: https://www.psychiatrictimes.com/view/through-the-peaks-and-valleys-assessing-and-addressing-su***de-risk-in-bipolar-disorder

11/19/2025

Jail diversion programs reduce recidivism, improve health outcomes, and are cost-effective compared with traditional incarceration. https://www.psychiatrictimes.com/view/breaking-the-cycle-jail-diversion-as-an-alternative-to-incarceration-for-individuals-with-co-occurring-disorders

11/19/2025

📣 A New Era in Clozapine Education
Are you confident prescribing clozapine?
Through a partnership between S&PAA and AAPP: Clozapine Education Modules, designed for busy prescribers who want expert, evidence-based answers—fast.
From “When do I start?” to “How do I manage side effects?”
Featuring expert, Megan Ehret, PharmD, MS, BCPP, FAAPP
Short, focused modules—each under an hour

🔗Don’t miss your chance to be the first to access this FREE learning series: https://hubs.li/Q03SF_5y0

&PAA

11/14/2025

The FDA has granted a label expansion for the deep transcranial magnetic stimulation system that makes the treatment available as an adjunct therapy for adolescents aged 15 to 21 years who have major depressive disorder.

FDA expands Deep TMS therapy for adolescents with major depressive disorder, offering a noninvasive treatment option for underserved youth.

11/14/2025

Placebo treatments can yield clinically meaningful improvements across psychiatric disorders. A new study found the strongest effects in depression and anxiety, and the weakest effects seen in schizophrenia and OCD.

Explore how placebo effects vary across psychiatric disorders, revealing significant symptom improvements, especially in major depressive disorder and generalized anxiety disorder.

11/13/2025

In the Vibrance-2 study, once-daily alixorexton met the dual primary endpoints, demonstrating statistically significant and clinically meaningful improvements from baseline compared with placebo on the Maintenance of Wakefulness Test and Epworth Sleepiness Scale at week 8.

Alixorexton shows promising results in improving wakefulness and reducing daytime sleepiness in patients with narcolepsy type 2.